The burgeoning landscape of innovative treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a similar https://bookmarkbells.com/story20770798/retatrutide-vs-tirzepatide-a-comparative-analysis